Allogene hit with FDA clinical hold after a patient experiences 'abnormality' in CAR-T cells — shares hammered
The FDA has slapped a clinical hold on Allogene’s clinical trials after a patient in one of their early-stage studies for the off-the-shelf cell therapy ALLO-501A developed a “chromosomal abnormality” in their CAR-T cells.
The biotech $ALLO reported after the market close on Thursday that executives plan to follow up in the coming weeks with regulators as the FDA considers the biotech’s plan to take this drug into a pivotal trial.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.